Brief: Adicet Says Co Expanding Clinical Development Of ADI-001 Into Autoimmune Diseases

ADICET Bio

04/01/2024 12:03

Jan 4 (Reuters) - Adicet Bio Inc  ACET.O :
    * ADICET PROVIDES CORPORATE UPDATE AND HIGHLIGHTS STRATEGIC
PRIORITIES FOR 2024
    * ADICET BIO INC - ADI-001 CLINICAL UPDATE EXPECTED 2H 2024
    * ADICET BIO INC - ADI-270 IND SUBMISSION IN RENAL CELL
CARCINOMA
EXPECTED IN 2Q 2024
    * ADICET BIO INC - UPDATED CASH RUNWAY INTO 2H 2025
    * ADICET BIO - EXPANDING CLINICAL DEVELOPMENT OF ADI-001
INTO
AUTOIMMUNE DISEASES FOLLOWING CLEARANCE OF IND; TO INITIATE
PHASE 1 CLINICAL STUDY IN 2Q
    * ADICET BIO: FOCUSING ENROLLMENT ON MCL IN ONGOING ADI-001
PHASE
1 CLINICAL TRIAL GIVEN FAVORABLE COMPLETE RESPONSE (CR) RATE,
DURABILITY, AND SAFETY

Source text for Eikon:  ID:nBw3wVrsRa 
Further company coverage:  ACET.O 

 ((Reuters.Briefs@thomsonreuters.com;))